---
title: "Efficacy of Vancomycin vs Fidaxomicin (Fixed and Pulse‑Taper) to Prevent Recurrent Clostridioides"
id: "medrxiv-11-comparative-efficacy-of-vancomycin-and-fidaxomicin-regimens-for-the-prevention"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-comparative-efficacy-of-vancomycin-and-fidaxomicin-regimens-for-the-prevention"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.14.26358112v1?rss=1"
published_at: "2026-07-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Efficacy of Vancomycin vs Fidaxomicin (Fixed and Pulse‑Taper) to Prevent Recurrent Clostridioides
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-comparative-efficacy-of-vancomycin-and-fidaxomicin-regimens-for-the-prevention
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.14.26358112v1?rss=1)
- **Published At:** 2026-07-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This systematic review and network meta-analysis included 8 randomized controlled trials totaling 2,181 patients to compare **vancomycin** and **fidaxomicin** regimens for preventing recurrent Clostridioides difficile infection (CDI). - The literature search covered MEDLINE and CENTRAL through May 21, 2025, plus recent conference abstracts; RCTs compared fixed-dose (10–14 days) and pulse-and-taper (P‑T) regimens for first episodes or first recurrences. - Primary outcome was 40‑day CDI recurrence; secondary outcome was 56‑day recurrence. A random‑effects network meta‑analysis used standard 10–14 day vancomycin as the comparator and ranked treatments by SUCRA. - For 40‑day recurrence, **fidaxomicin pulse‑taper** had the highest probability of being best (RR 0.10, 95% CI 0.10–0.49; SUCRA 1.00). - **Vancomycin pulse‑taper** reduced 40‑day recurrence versus standard vancomycin (RR 0.49, 95% CI 0.32–0.76; SUCRA 0.61). - **Fixed‑dose fidaxomicin** also lowered 40‑day recurrence compared with fixed‑dose vancomycin (RR 0.61, 95% CI 0.49–0.76; SUCRA 0.39). - Fixed‑dose vancomycin ranked lowest (SUCRA 0.00) for preventing recurrence at 40 days. - The same ranking order was observed for 56‑day recurrence, but only 3 RCTs reported that timepoint; the manuscript did not provide further numeric detail for 56‑day outcomes beyond the ranking. - Authors conclude that vancomycin P‑T, fidaxomicin P‑T, and fixed‑dose fidaxomicin were superior to fixed‑dose vancomycin; they call for head‑to‑head RCTs to quantify comparative effect sizes and long‑term prevention impact. - The article is a preprint and has not undergone peer review; ethical and competing interest statements were reported as described in the source.
## Clinical Analysis & Structured Key Points
Skip to main content HOMESUBMITFAQBLOGALERTS / RSSRESOURCESABOUT Search for this keyword Advanced Search Follow this preprint Comparative Efficacy of Vancomycin and Fidaxomicin Regimens for the Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials Connor Prosty, View ORCID Profile Guillaume Butler-Laporte, James Brophy, Charles Frenette, Vivan Loo, Bryan Coburn, Susy Hota, Yves Longtin, Ling Kong, Matthew Muller, Theodore Steiner, Louis Valiquette, Nick Daneman, Peter Daley, Caroline Nott, Derek R. MacFadden, Christopher Kandel, Yan Chen, Santiago Perez- Patrigeon, Todd C Lee, Emily McDonald doi: https://doi.org/10.64898/2026.07.14.26358112 This article is a preprint and has not been certified by peer review [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice. AbstractInfo/HistoryMetrics Preview PDF Abstract Background and Aims The optimal treatment for first episodes and first recurrences of Clostridioides difficile infections (CDI) is unknown and there is emerging evidence for pulse and taper (P-T) regimens. Therefore, we sought to estimate the relative efficacy of treatment options. Methods MEDLINE and CENTRAL were searched from database inception to May 21, 2025 and unpublished conference abstracts were searched from recent infectious disease conferences. RCTs on the treatment of first episodes or first recurrences of CDI comparing fixed-dose or P-T regimens of fidaxomicin or vancomycin were included. The primary and secondary outcomes were 40- and 56-day CDI recurrence, respectively. A random-effects network meta-analysis on the risk ratio (RR) scale was conducted using a standard regimen (10-14 days) of vancomycin as the comparator. Treatments were ranked using the surface under the cumulative ranking curve (SUCRA). Results 8 RCTs were included comprising a total of 2181 patients. For 40-day recurrence, fidaxomicin P-T had the highest probability of ranking best (RR=0.10, 95%Confidence Interval [95%CI]=0.10-0.49, SUCRA=1.00), followed by vancomycin P-T (RR=0.49, 95%CI=0.32-0.76, SUCRA=0.61), fixed-dose fidaxomicin (RR=0.61, 95%CI=0.49-0.76, SUCRA=0.39), and, finally, fixed-dose of vancomycin (SUCRA=0.00). The treatments ranked in the same order for 56-day recurrence, though only 3 RCTs reported on this timepoint. Conclusion Vancomycin P-T, fidaxomicin P-T, and fixed-dose fidaxomicin were all superior to a fixed-dose vancomycin. Head-to-head comparative effectiveness RCTs are needed to quantify their relative effect sizes of and impact on long-term prevention of recurrent CDI. Competing Interest Statement Drs. McDonald, Lee, Longtin, and Butler-Laporte receive salary support from the Fonds de Recherche du Quebec - Sante outside of this work. Drs. McDonald, Lee, Prosty, Longtin, Coburn, Hota, Muller, Steiner, Daneman, Daley, MacFadden, Kandel, Chen, Perez-Patrigeon are co-applicants on a Canadian Institutes of Health Research-funded C. difficile platform clinical trial. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study used ONLY openly available human data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. Donate to openRxiv Back to top Previous Next Posted July 17, 2026. Download PDF Print/Save Options Author Declarations Supplementary Material Data/Code Email Share Citation Tools Get QR code Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos Subject Areas All Articles Addiction Medicine Allergy and Immunology Anesthesia Cardiovascular Medicine Dentistry and Oral Medicine Dermatology Emergency Medicine Endocrinology (including Diabetes Mellitus and Metabolic Disease) Epidemiology Forensic Medicine Gastroenterology Genetic and Genomic Medicine Geriatric Medicine Health Economics Health Informatics Health Policy Health Systems and Quality Improvement Hematology HIV/AIDS Infectious Diseases (except HIV/AIDS) Intensive Care and Critical Care Medicine Medical Education Medical Ethics Nephrology Neurology Nursing Nutrition Obstetrics and Gynecology Occupational and Environmental Health Oncology Ophthalmology Orthopedics Otolaryngology Pain Medicine Palliative Medicine Pathology Pediatrics Pharmacology and Therapeutics Primary Care Research Psychiatry and Clinical Psychology Public and Global Health Radiology and Imaging Rehabilitation Medicine and Physical Therapy Respiratory Medicine Rheumatology Sexual and Reproductive Health Sports Medicine Surgery Toxicology Transplantation Urology Evaluation/discussion of this paper x 0 0 0 0 0 0 We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. Continue Find out more
## Related Clinical Research

- [Agentic-TimesFM-AKI: Dual LLM–Time Series System for Predicting Drug-Induced Acute Kidney Injury](https://medichelpline.com/clinical-feed/medrxiv-3-agentic-timesfm-aki-a-dual-llm-time-series-framework-for-predicting-drug.md)
- [Early oral fecal microbiota transplantation versus vancomycin or fidaxomicin for first or first-re](https://medichelpline.com/clinical-feed/bmj-open-13-fecal-microbiota-transplantation-versus-vancomycin-or-fidaxomicin-in.md)
- [Citrobacter freundii Identified as Pathogen Causing Disease in Farmed Singhi (Heteropneustes fossi](https://medichelpline.com/clinical-feed/pubmed-42424302.md) (DOI: 10.1093/jahafs/vsag006)
- [Polystyrene microplastics increase Clostridioides difficile biofilms and reduce antibiotic suscept](https://medichelpline.com/clinical-feed/pubmed-42535848.md) (DOI: 10.1128/aem.01168-26)
- [Replace the term “red man syndrome” with vancomycin infusion reaction in clinical use](https://medichelpline.com/clinical-feed/cmaj-5-red-man-syndrome-should-never-be-used-to-describe-vancomycin-infusion-reaction.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.